Thinking of Multi-Cancer Early Detection out of the box

Rivela diagnostics

Pioneers & specialists in Exosome biology

Rivela Diagnostics Ltd was established in 2022 to complete the R&D work started by its parent company Exosomics Inc, and to bring to the marketplace a propietary approach and assets on multicancer screening. Exosomics and its subsidiary HansaBioMed Life Sciences, have lead the exosome space in Europe since 2011. Lonza has recently acquired Exosomics' business unit in Siena (Italy) to expand its exosome service offering worldwide and to strengthen Lonza's position as a leading global CDMO in exosomes bioprocessing. 

Based in the UK, RivelaDx Ltd will work with leading European research centres and industrial partners to bring to global markets a sustainable and reliable multi-cancer and pan-cancer testing approach.

Innovation and Revolution in Multi-Cancer Screening / Innovation and Revolution in Multi-Cancer Screening /
RivelaDx Management

Antonio Chiesi

Chief Scientific Officer

Antonio Chiesi is the Founder and CEO of Exosomics Inc and HansaBioMed Ltd, both established to bring to commercial exploitation products for exosome research and exosome-based diagnostics emerging from his previous research at the Italian National Institute of Health (ISS) in Rome, where he acted as Head of Clinical Research for over 20 years. At the ISS, before leading intramural research in the exosome and cancer metabolism in the early years 2000, he led programs in Neuro HIV at a national level since 1990 and was engaged in several plans for early clinical development of anti-HIV drugs at EU Commission level. As a Startupper he raised over 10M euro from VCs and Industries (Lonza and Agilent) on Exosomics Inc up to the acquisition by Lonza of the business unit based in Siena, and brought to global commercial success HansaBioMed as the only and oldest exosome focused company. Currently he is engaged in Rivela Diagnostics, the new spin off of Exosomics Inc, aimed at bringing to the market a ground breaking approach to multi-cancer screening.

Antonio graduated as a Medical Doctor at the University of Roma La Sapienza in 1988 where he also got a Specialization in Neurology in 1992.  

Natasa Zarovni

Chief Technology Officer

Natasa Zarovni is a trained molecular biologist and physiologist with a PhD in Molecular Medicine from Open London University and University Vita Salute in Milan, and an over decade long academic research and project management experience in gene therapy, cancer immunology, stem cells, functional genomics. She has joined HansaBiomed and Exosomics as a member of the founding team and has worked as the R&D and Strategic Innovation Leader on building up the team, the IP portfolio, product pipeline and grants supported projects. Over last 13 years she has established herself as an “Exosome expert and enthusiast”, with excellent scientific and non-dilutive fund-raising track record. Through her active promotion and participation in over 20 collaborative projects, she has been supporting the growth of the overall EV Innovation and Research-to-Business ecosystem across EU.

RivelaDx Board of Directors

Information on cookies on this site

This site uses anonymous technical and statistical cookies, necessary for its operation.

Read more x